Skip to content
10-K

Annual Report

TScan Therapeutics, Inc. TCRX

0000950170-25-033077

← back to feed
Filed
Mar 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2023 65.6M sh
Capex FY 2024 · Dec 31, 2023 $3.15M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$61.36M
Long Term Debt FY 2024 · Dec 31, 2023 $26.7M
Short Term Debt FY 2024 · Dec 31, 2023 $3.35M
Cash And Equivalents FY 2024 · Dec 31, 2023 $133.36M
Current Liabilities FY 2024 · Dec 31, 2023 $29.82M
Total Liabilities FY 2024 · Dec 31, 2023 $121.28M
Current Assets FY 2024 · Dec 31, 2023 $194.24M
Total Assets FY 2024 · Dec 31, 2023 $272.15M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.36
Eps Basic FY 2024 · Dec 31, 2023 −$1.36
Sga Expense FY 2024 · Dec 31, 2023 $26.35M
Rd Expense FY 2024 · Dec 31, 2023 $88.15M
Net Income FY 2024 · Dec 31, 2023 −$89.22M
Operating Income FY 2024 · Dec 31, 2023 −$93.46M
Revenue FY 2024 · Dec 31, 2023 $21.05M
Stockholders Equity FY 2024 · Dec 31, 2022 $99.43M